{
    "organizations": [],
    "uuid": "b4ff9ee1989f3c543f1de07a71338549af8e53f3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-heat-biologics-interim-results-fro/brief-heat-biologics-interim-results-from-phase-2-study-investigating-hs-110-in-combination-with-anti-pd-1-idUSFWN1QI0T6",
    "ord_in_thread": 0,
    "title": "BRIEF-Heat Biologics - Interim Results From Phase 2 Study Investigating HS-110 In Combination With Anti-PD-1",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 28 (Reuters) - Bristol-Myers Squibb Co:\n* HEAT BIOLOGICS - INTERIM RESULTS FROM PHASE 2 STUDY INVESTIGATING HS-110 IN COMBINATION WITH BRISTOL-MYERS‘S ANTI-PD-1 CHECKPOINT INHIBITOR, NIVOLUMAB\n* HEAT BIOLOGICS SAYS COMBINATION OF HS-110 AND NIVOLUMAB WAS WELL TOLERATED - SEC FILING\n* HEAT BIOLOGICS - IN PHASE 2 CLINICAL TRIAL OF HS-110 AND NIVOLUMAB, OVERALL RESPONSES APPEARED DURABLE AND LONG LASTING‍​ Source text ( bit.ly/2BTjnp7 ) Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ",
    "published": "2018-02-28T20:05:00.000+02:00",
    "crawled": "2018-03-01T21:08:47.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "squibb",
        "co",
        "heat",
        "biologics",
        "interim",
        "result",
        "phase",
        "study",
        "investigating",
        "combination",
        "checkpoint",
        "inhibitor",
        "nivolumab",
        "heat",
        "biologics",
        "say",
        "combination",
        "nivolumab",
        "well",
        "tolerated",
        "sec",
        "filing",
        "heat",
        "biologics",
        "phase",
        "clinical",
        "trial",
        "nivolumab",
        "overall",
        "response",
        "appeared",
        "durable",
        "long",
        "source",
        "text",
        "company",
        "coverage"
    ]
}